Skip to main content
Fig. 5 | BMC Rheumatology

Fig. 5

From: Circulating exo-miRNA-27a-5p is a novel biomarker of the tofacitinib treatment response in rheumatoid arthritis

Fig. 5

Impact of tofacitinib therapy on the expression of potential exomiRNAs. (a) Levels of exo-miR-27a-5p before and after tofacitinib therapy. (b–d) Correlation analysis of exo-miR-27a-5p expression with DAS28, ESR, and RF before and after tofacitinib treatment. (e) ROC analysis of the sensitivity and specificity between changes in the expression of exo-miR-27a-5p and tofacitinib therapy. Values are normalized to CelmiRNA-39-3p and are shown on a log10 scale on the 𝑦-axis. All data are shown as the mean ± SD. ****p < 0.0001, ***p < 0.001, ** p < 0.01, * p < 0.05

Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us